氨甲环酸在胃肠道出血中的应用:系统评价与荟萃分析
5项试验评估长时程高剂量静脉氨甲环酸,7项评估低剂量静脉或肠内氨甲环酸。长时程高剂量静脉氨甲环酸未降低死亡率(RR 0.98,95%CI 0.88-1.09,高确定性)或出血(RR 0.92,95%CI 0.82-1.04,高确定性),但增加深静脉血栓(RR 2.01,95%CI 1.08-3.72)、肺栓塞(RR 1.78,95%CI 1.06-3.0)和癫痫发作(RR 1.73,95%CI 1.03-2.93)。低剂量静脉/肠内氨甲环酸未降低死亡率(RR 0.62,95%CI 0.36-1.09),但减少再出血(RR 0.5,95%CI 0.33-0.75)和手术需求(RR 0.58,95%CI 0.38-0.88),中等确定性。
要点
- 长时程高剂量静脉氨甲环酸不降低胃肠道出血患者死亡率(RR 0.98,95%CI 0.88-1.09;高确定性)和出血风险(RR 0.92,95%CI 0.82-1.04;高确定性)。
- 长时程高剂量静脉氨甲环酸增加深静脉血栓(RR 2.01,95%CI 1.08-3.72)、肺栓塞(RR 1.78,95%CI 1.06-3.0)和癫痫发作(RR 1.73,95%CI 1.03-2.93),均为高确定性。
- 低剂量静脉/肠内氨甲环酸未降低死亡率(RR 0.62,95%CI 0.36-1.09),但减少再出血(RR 0.5,95%CI 0.33-0.75)和手术需求(RR 0.58,95%CI 0.38-0.88),中等确定性。
- 低剂量/肠内氨甲环酸的安全性证据不足,需更多证据验证。
- 基于上述结果,不推荐对胃肠道出血患者常规使用长时程高剂量静脉氨甲环酸。
适用人群与场景
- 成人胃肠道出血患者,纳入随机对照试验比较氨甲环酸与常规治疗或安慰剂。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 长时程高剂量静脉氨甲环酸:原文未提及具体剂量、给药途径、频次或疗程。
- 低剂量静脉或肠内氨甲环酸:原文未提及具体剂量、给药途径、频次或疗程。
红旗征与不能漏的情况
- 使用长时程高剂量静脉氨甲环酸时,需警惕深静脉血栓、肺栓塞和癫痫发作风险增加。
研究设计与关键结果
- 长时程高剂量静脉氨甲环酸 vs 其他剂量策略:死亡率RR 0.98(95%CI 0.88-1.09;I2=63%;高确定性);出血RR 0.92(95%CI 0.82-1.04;p=0.17;绝对风险差-0.7%,95%CI -1.5至0.3;高确定性)。
- 长时程高剂量静脉氨甲环酸增加深静脉血栓(RR 2.01,95%CI 1.08-3.72;I2=0%)、肺栓塞(RR 1.78,95%CI 1.06-3.0;I2=0%)和癫痫发作(RR 1.73,95%CI 1.03-2.93),高确定性。
- 低剂量静脉/肠内氨甲环酸 vs 其他:死亡率RR 0.62(95%CI 0.36-1.09;I2=0%);再出血RR 0.5(95%CI 0.33-0.75;I2=9%);手术需求RR 0.58(95%CI 0.38-0.88;I2=11%),中等确定性。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,纳入随机对照试验。
- 证据等级:采用GRADE方法评估,长时程高剂量静脉氨甲环酸相关结局为高确定性,低剂量/肠内氨甲环酸相关结局为中等确定性。
- 局限:原文未明确提及;设计上为荟萃分析,异质性(如死亡率I2=63%)需考虑。
对床旁实践的改变
- 不推荐对胃肠道出血成人患者常规使用长时程高剂量静脉氨甲环酸,因其不改善死亡率或出血结局且增加血栓栓塞和癫痫风险。
- 低剂量静脉/肠内氨甲环酸可能减少再出血和手术需求,但安全性证据不足,需个体化权衡。
- 适用人群:成人胃肠道出血患者;不适用人群原文未提及。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Tranexamic acid is proposed as a treatment for gastrointestinal bleeding. The Haemorrhage Alleviation with Tranexamic Acid-Intestinal System trial evaluated extended-use (24 hr) high-dose tranexamic acid, prompting a reappraisal for tranexamic acid in gastrointestinal bleeding.
DATA SOURCES: We conducted a systematic review and meta-analysis of randomized controlled trials comparing tranexamic acid with usual care or placebo in adults with gastrointestinal bleeding. We searched MEDLINE, EMBASE, and CENTRAL (inception to September 2019).
DATA SELECTION: Two reviewers independently screened citations, extracted data, and assessed the risk of bias using the Cochrane risk of bias tool in duplicate. The main outcomes were mortality, bleeding, and adverse events.
DATA EXTRACTION: Studies were analyzed as high-dose IV tranexamic acid versus all other dosing strategies for tranexamic acid using fixed-effects models. We assessed certainty of evidence using the Grading of Recommendations Assessment, Development, and Evaluation approach.
DATA SYNTHESIS: Five randomized controlled trials evaluated extended-use high-dose IV tranexamic acid, seven evaluating low-dose IV or enteral tranexamic acid. Extended-use high-dose IV tranexamic acid did not reduce mortality (relative risk, 0.98%; 95% CI, 0.88-1.09; I2 = 63%; high certainty) or bleeding (relative risk, 0.92; 95% CI, 0.82-1.04; p = 0.17 and absolute risk differences, -0.7%; 95% CI, -1.5 to 0.3; high certainty) but resulted in a small increase in deep venous thrombosis (relative risk, 2.01; 95% CI, 1.08-3.72; I2 = 0%), pulmonary embolism (relative risk, 1.78; 95% CI, 1.06-3.0; I2 = 0%), and seizure (relative risk, 1.73; 95% CI, 1.03-2.93) with high certainty. Low-dose IV/enteral tranexamic acid did not reduce mortality (relative risk, 0.62; 95% CI, 0.36-1.09; I2 = 0%) but did reduce risk of rebleeding (relative risk, 0.5; 95% CI, 0.33-0.75; I2 = 9%) and need for surgery (relative risk, 0.58; 95% CI, 0.38-0.88; I2 = 11%), with moderate certainty.
CONCLUSIONS: Extended-use high-dose IV tranexamic acid does not improve mortality or bleeding outcomes and increases adverse events. Low-dose/enteral tranexamic acid may be effective in reducing hemorrhage; more evidence is required to demonstrate its safety.
参考来源
- Dionne JC, Oczkowski SJW, Hunt BJ, et al. Tranexamic Acid in Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis. Crit Care Med. 2022. PMID: 34709209. doi:10.1097/CCM.0000000000005362
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。